Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons

• Published in: Sexually transmitted diseases 2001-06, Vol.28 (6), p.343-346
• Main Authors: MATTEELLI, Alberto, BELTRAME, Anna, GRAIFEMBERGHI, Severo, FORLEO, Maria Antonietta, GULLETTA, Maurizio, CIRAVOLO, Giuseppe, TEDOLDI, Simona, CASALINI, Catia, CAROSI, Giampiero
• Format: Article
• Language: English
• Subjects: Administration, Cutaneous; Adult; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Anus Diseases - complications; Anus Diseases - drug therapy; Biological and medical sciences; Cidofovir; Cytosine - administration & dosage; Cytosine - analogs & derivatives; Cytosine - therapeutic use; Female; Female Urogenital Diseases - complications; Female Urogenital Diseases - drug therapy; HIV Infections - complications; Humans; Male; Male Urogenital Diseases; Medical sciences; Organophosphonates; Organophosphorus Compounds - administration & dosage; Organophosphorus Compounds - therapeutic use; Patient Satisfaction; Pharmacology. Drug treatments; Pilot Projects; Single-Blind Method; Treatment Outcome; Tumor Virus Infections - complications; Tumor Virus Infections - drug therapy; Warts - complications; Warts - drug therapy
• ISSN: 0148-5717; 1537-4521
• DOI: 10.1097/00007435-200106000-00007

Treatment options for anogenital warts in patients with HIV-1 are unsatisfactory because they fail to eradicate latent human papillomavirus. To determine tolerability and efficacy of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected patients. A randomized, placebo-controlled, single-blind, crossover pilot study of either 1% cidofovir cream or placebo applied once daily 5 days a week for 2 weeks followed by 2 weeks of observation was performed. Six patients were randomized to 1% cidofovir cream and six to placebo. The latter patients eventually received 1% cidofovir cream. Thus, 12 treatment rounds of cidofovir were compared with six rounds of placebo. A reduction of more than 50% in the total wart area achieved by seven cidofovir treatments (58%), as compared with no placebo regimen (P = 0.02). Local reactions occurred in 10 of the 12 patients treated with cidofovir, as compared with 0 of the 6 subjects in the placebo group (P < 0.001). For the initial clearance of anogenital warts in HIV-infected patients, 1% cidofovir cream is significantly more effective than vehicle cream. Local mucosal erosion is a common side effect.